NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Market Expansion Horizon | Novocure targets new oncology markets with $38 price target, balancing innovation against adoption challenges and R&D investments |
Patient-Centric Advances | FDA approval of Head Flexible Electrode arrays aims to enhance comfort and compliance, potentially boosting treatment efficacy and revenue |
Clinical Breakthroughs | PANOVA-3 trial results reveal significant survival benefits for pancreatic cancer patients, potentially opening new market opportunities |
Innovative Cancer Tech | Novocure's TTFields therapy disrupts cancer cell division, showing promise in treating aggressive tumors like glioblastoma multiforme |
Metrics to compare | NVCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.2x | −3.6x | −0.5x | |
PEG Ratio | −0.46 | −0.12 | 0.00 | |
Price / Book | 4.1x | 4.0x | 2.6x | |
Price / LTM Sales | 2.1x | 5.0x | 3.2x | |
Upside (Analyst Target) | 108.5% | 54.1% | 45.7% | |
Fair Value Upside | Unlock | 8.6% | 4.8% | Unlock |